Polyamines detection with MR spectroscopy to increase diagnostic specifity in prostate cancer

Polyamines detection with MR spectroscopy to increase diagnostic specifity in prostate cancer - Polyamines in prostate cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON40868

Enrollment

Registered

2014-07-15

Start date

2014-06-01

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer.

Interventions

MRSI scan will be extended by 20 minutes

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients with biopsy*proven prostate cancer who are eligible for a brachytherapy screening MRI exam of the prostate with an endorectal coil.

Exclusion criteria

Exclusion criteria: • Contra-indications for a MRI exam according to the standard protocol for the screening of patients with prostate cancer • Treatment of prostate cancer prior to the MRI exams, including hormonal therapy and trans-urethral resection (TURP)

Design outcomes

Primary

Measure	Time frame
To show the feasibility of acquiring 1H MRSI in prostate with reduced chemical shift artifacts at 3T using the FOCI RF pulses in a editing semi-LASER sequence. Quantification for comparison of the metabolite concentrations will be obtained with the LC model.	—

Secondary

Measure	Time frame
N.A	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)